Twelve patients with malignant pleural mesothelioma were subjected to mitomycin C (MMC) and vindesine (VDS) chemotherapy (MMC 10 mg/m2, i.v., d 1; VDS, 3 mg/m2, i.v., d 1–8, every 4 weeks). No objective response was obtained; 3 (25%) patients had stable disease and 9 (75%) progression of disease. We conclude that MMC plus VDS is an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
Get full access to this article
View all access options for this article.
References
1.
AisnerJ., WiernikP.H.: Malignant mesothelioma: current status and future prospects.Chest, 74: 438–444, 1980.
2.
AlbertsA.S., FalksonG., GoedhalsL., VorobiofD.A.: Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.J. Clin. Oncol., 6: 527–535, 1988.
3.
AntmanK.H., BlumR.H., GreenbergerJ.S.: Multimodality therapy for malignant mesothelioma based on a study of natural history.Am. J. Med., 68: 356–362, 1980.
4.
AntmanK.H., SheminR., RyanL.: Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985.J. Clin. Oncol., 6: 147–153, 1988.
5.
BajorinD., KelsenD., MintzerD.M.: Phase II trial of mitomycin in malignant mesothelioma.Cancer Treat. Rep., 71: 857–858, 1987.
6.
BoutinC., IrrissonM., GuerinJ.C., RoegelE., ParamelleB., BrambillaC., JeannineL., DabouisG., LecaerH., ViallatJ.R.: Phase II trial of vindesine in malignant pleural mesothelioma.Cancer Treat. Rep., 71: 205–207, 1987.
7.
ButchartE.G., AschroftT., BarnsleyW.C.: Pleuropneumectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients.Thorax, 31: 15–24, 1976.
8.
ChahinianA.P., AntmanK., AisnerJ., PropertK., ModeasC., EllisonR.R., StollD.B., GreenM.: Cisplatin with adriamycin or mitomycin for malignant mesothelioma: a randomized phase II trial.Proc. Am. Soc. Clin. Oncol., 6: 183: 1987.
9.
GarewalH.S., BrooksR.J., JonesS.E., MillerT.P.: Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.J. Clin. Oncol., 1: 772–775, 1983.
10.
KelsenD., GrallaR., ChengE.: Vindesine in the treatment of malignant mesothelioma. A phase II study.Cancer Treat. Rep., 67: 821–822, 1983.
11.
KrisM.G., GrallaR.J., KelsenD.P.: Trial of vindesine plus mitomycin in stage III non small cell lung cancer. An active regimen for out-patient treatment.Cancer Treat. Rep., 66: 1291–1297, 1982.
12.
LuedkeD.W., LuedkeS.L., MarteloO., QuesenberryP., BirchR., SchlueterJ., HakeJ., LoganT.: Vindesine and mitomycin in the treatment of advanced non small cell lung cancer: a Southern Cancer Group trial.Cancer Treat. Rep., 70: 651–653, 1986.
13.
MbiddeE.K., HarlandS.J., CalvertA.H., SmithI.: Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.Cancer Chemother. Pharmacol., 18: 284–285, 1986.
14.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
15.
MinzerD.M., KelsenD., FrimmerD.: Phase II high dose cisplatin in patients with malignant mesothelioma.Cancer Treat. Rep., 69: 711–712, 1985.
16.
RuffleP., FeldR., MinkinS., CormierY., Boutan-LarozeA., GinsbergR., AyoubJ., SheperdF.A., EvansW.K., FigueredoA., PaterJ.L., PringleJ.F., KreismanH.: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 32 patients.J. Clin. Oncol., 7: 1157–1168, 1989.
17.
SorensenP.G., BachF., BorkE., HansenH.H.: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.Cancer Treat. Rev., 69: 1431–1432, 1985.
18.
ZidarB.L., PughR.P., SchifferL.M., RajuR.N., VaidyaK.A., BloomR.L., HomeD., BakerL.H.: Treatment of six cases of mesothelioma with doxorubicin and cisplatin.Cancer, 52: 1788–1791, 1983.
